Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06292780 | 1, 2 | A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) | BCMA -- bispecific antibody (Linvoseltamab) |
| NCT05651932 | 1 | A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | MMSET (NSD2/WHSC1) -- small molecule inhibitor |
| NCT07222761 | 3 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | BCMA -- bispecific antibody (T cell engager); Proteasome -- proteasome inhibitor; CD38 -- monoclonal antibody; glucocorticoid receptor -- steroid; Cereblon modulator -- immunomodulation |
| NCT07555938 | 3 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | FcRH5 -- bispecific antibody |
| NCT06768489 | 1 | A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 30 |
| Janssen Research & Development, LLC | 12 |
| Regeneron Pharmaceuticals | 10 |
| Memorial Sloan Kettering Cancer Center | 10 |
| Xuzhou Medical University | 9 |
Countries/regions with the most active trial sites for multiple myeloma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jun 30, 2027 | NCT06435910 | Engineered Dendritic Cell Vaccines for Multiple Myeloma | Tumor antigens -- dendritic cell vaccine |
| Jun 30, 2027 | NCT06006741 | Universal CAR-T Cells Targeting Multiple Myeloma | Multiple myeloma antigens -- universal chimeric antigen receptor T cell therapy (CAR-T) |
| Apr 12, 2027 | NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment | BCMA + CD3 -- bispecific antibody (teclistamab); Cereblon modulator (pomalidomide); Proteasome inhibitor (carfilzomib) |
| Dec 31, 2026 | NCT06429150 | Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | Multiple myeloma antigens -- CAR-T cell therapy |
| Dec 31, 2026 | NCT03271632 | Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma | Multiple cancer cell surface antigens -- chimeric antigen receptor (CAR) T cell therapy |
| Dec 1, 2026 | NCT07600151 | Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | CD38 -- monoclonal antibody (isatuximab); Proteasome -- proteasome inhibitor (bortezomib); Cereblon -- immunomodulatory agent (lenalidomide); Glucocorticoid receptor -- corticosteroid (dexamethasone); Unknown mechanism (etentamig) |
| Dec 1, 2026 | NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma | BCMA -- CAR-T cells and bispecific antibody |
| Dec 2026 | NCT07831122 | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | BCMA + CD3 -- bispecific antibody (cevostamab); BCMA -- antibody-drug conjugate (belantamab mafodotin) |
You've seen the multiple myeloma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.